UNLIMITED FREE ACCESS TO THE WORLD'S BEST IDEAS

SUBMIT
Already a GlobalSpec user? Log in.

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

Customize Your GlobalSpec Experience

Finish!
Privacy Policy

This is embarrasing...

An error occurred while processing the form. Please try again in a few minutes.

- Trained on our vast library of engineering resources.

CLSI - EP07

Interference Testing in Clinical Chemistry

active, Most Current
Organization: CLSI
Publication Date: 1 April 2018
Status: active
Page Count: 122
scope:

This guideline is intended for manufacturers and medical laboratories, for two purposes:

• Assist manufacturers and other developers of laboratory measurement procedures in characterizing the effects of potential interferents on measurement procedures results by providing information on:

- Relevant interferents and concentrations to be tested

- Likely effects of the interferent on the concentration of the measurand of interest (ie, no effect, positive effect, or negative effect)

- Scientifically valid experimental designs

- Appropriate data analysis and interpretation

- Stating meaningful interference claims

• Assist medical laboratories in investigating discrepant results that may be due to interferents by:

- Defining a systematic investigation strategy

- Specifying data collection and analysis procedures

- Promoting greater cooperation between laboratory scientists and manufacturers so that new interferents are identified, disclosed, and ultimately eliminated

Any measurement procedure, quantitative or qualitative, may be subject to interference. This guideline is written for a broad spectrum of measurement procedures and measuring systems, with primary focus on quantitative methods and qualitative methods with interpretation based on numeric values. Modification may be necessary to accommodate the particular characteristics of the procedure being evaluated. Measurement procedures that use serum, plasma, whole blood, cerebrospinal fluid, urine, and most other body fluids can be evaluated for interferents using this guideline.

EP07 and its supplement, CLSI document EP37,1 are not meant to include a complete list of interferents to be tested and do not stipulate that all potential interferents included in CLSI document EP371 are to be tested. However, EP07 and CLSI document EP371 are intended to provide a solid starting point for assessing interference effects. This guideline is limited to testing potential interference from chemical substances that may be exogenous (eg, drugs) or endogenous changes in concentrations of substances caused by disease processes (eg, bilirubin, lipoproteins).

This guideline does not cover potential interference from physiological conditions (eg, pregnancy, diurnal effects) or effects from environmental conditions (eg, heat, sunlight).

Document History

April 1, 2018
Interference Testing in Clinical Chemistry
Clinical and Laboratory Standards Institute guideline EP07—Interference Testing in Clinical Chemistry is intended to promote uniformity in the evaluation of interference characteristics of medical...
EP07
April 1, 2018
Interference Testing in Clinical Chemistry
This guideline is intended for manufacturers and medical laboratories, for two purposes: • Assist manufacturers and other developers of laboratory measurement procedures in characterizing the...
November 1, 2005
Interference Testing in Clinical Chemistry; Approved Guideline
This document is intended to serve two purposes: 1) to assist manufactures and other developers of laboratory measurement procedures in characterizing the susceptibility of measurement procedures to...

References

Advertisement